Leap Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing treatments for various cancers. At the forefront of its pipeline is DKN-01, a monoclonal antibody designed to block Dickkopf-related protein 1 (DKK1). This investigational therapy is currently undergoing several clinical trials, targeting a range of malignancies such as esophagogastric, hepatobiliary, gynecologic, and prostate cancers.
| Date | Est. | Actual | |
|---|---|---|---|
| Mar 16, 2026 | -$0.20 | $0.92 | Beat |
| Nov 12, 2025 | -$0.24 | -$0.08 | Beat |
| Aug 14, 2025 | -$0.29 | -$0.40 | Miss |
| May 13, 2025 | -$0.38 | -$0.37 | Beat |
| Mar 26, 2025 | -$0.39 | -$0.37 | Beat |
| Nov 13, 2024 | -$0.46 | -$0.44 | Beat |